market until 2023 despite earlier entry in Europe
The sad part is those pts know the effect but do not want to stop and would rather take another antidepressant on the top and still it doesnt work the same for mood when they continue glp1
There are ongoing studies for these uses, but early data are weak and the risks are unknown
Although prospective studies specifically targeting PCOS + MASLD with pregnancy outcomes as the primary endpoint are currently lacking, a robust inference can be drawn based on the pathophysiological framework of MASLD and evidence from the general population: proactively identifying and reducing MASLD and ectopic fat load prior to pregnancy may be a key step in improving both periconception outcomes and long-term prognosis (76)
The findings, which were presented at the 61st ERA Congress Friday, suggest that receiving a weekly injection of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may help prevent complications like chronic kidney disease and end-stage renal disease that often occur alongside obesity
In combination with CJC-1295 No DAC, it acts on two distinct receptor pathways simultaneously